Moshe Y. Spinowitz, Skadden

Listen to this article

Moshe Y. Spinowitz joined the Boston office of Skadden in 2009 and quickly rose the ranks, ascending to the partnership in less than seven years.

Since his arrival, Spinowitz has played an instrumental role in growing Skadden’s robust Boston tax practice while himself advising a broad range of companies within the region’s life sciences and tech sectors and building an expertise in international tax matters, including cross-border mergers and acquisitions, supply chain planning,  international tax policy and tax reform.

Among Spinowitz’s key engagements as lead tax counsel, he recently represented Cambridge-based Alnylam Pharmaceuticals, Inc. in its $2.8 billion co-development and co-commercialization agreement with Switzerland’s Roche Holding AG to develop and commercialize the hypertension drug zilebesiran.

Additionally, Spinowitz counseled Ambrx Biopharma — a biopharmaceutical company developing next-generation antibody drug conjugates and other engineered therapies to modulate the immune system for the treatment of cancer — on its $2 billion acquisition by Johnson & Johnson.

Spinowitz also advised Brookfield Infrastructure Corporation in its $13.3 billion take-private acquisition of Triton International Limited in the fall of 2023. At a time when global supply chains were under immense pressure, the Canadian-U.S. transaction was one of the largest infrastructure and shipping deals announced that year. It included a cash/stock consideration, which was the first time Brookfield used the stock of its public parent (listed on both the Toronto stock-exchange and Nasdaq) to acquire a U.S. company.

The transaction included an equalization mechanic and a collar on the stock price in addition to multiple CFIUS and international antitrust filings in the EU, China, Korea and Switzerland.